Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 2694

Sort by

Sort Order Select

Journal Articles

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

Maria Teresa Voso, Giulia Falconi, Emiliano Fabiani

Blood (2021) 138 (9): 749–757.

https://doi.org/10.1182/blood.2021010764

Published: 2021

Journal Articles

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Dai Chihara, Graça M. Dores, Christopher R. Flowers, Lindsay M. Morton

Blood (2021) 138 (9): 785–789.

https://doi.org/10.1182/blood.2020010497

Published: 2021

Includes: Supplemental data

Journal Articles

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

Blood (2021) 138 (7): 557–570.

https://doi.org/10.1182/blood.2020009845

Published: 2021

Includes: Multimedia, Supplemental data

Journal Articles

The essential reading list for AML: the m 6 A transcripts

Kamil R. Kranc

Blood (2021) 138 (1): 6–7.

https://doi.org/10.1182/blood.2021011755

Published: 2021

Journal Articles

Blocking RiBi to suppress MYC lymphomagenesis

Jean-Francois Peyron

Blood (2021) 137 (24): 3316–3318.

https://doi.org/10.1182/blood.2020010620

Published: 2021

Journal Articles

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Blood (2021) 137 (24): 3403–3415.

https://doi.org/10.1182/blood.2020009023

Published: 2021

Includes: Supplemental data

Journal Articles

Emerging therapies for inv(16) AML

Sridevi Surapally, Daniel G. Tenen, John A. Pulikkan

Blood (2021) 137 (19): 2579–2584.

https://doi.org/10.1182/blood.2020009933

Published: 2021

Journal Articles

Modeling and targeting of erythroleukemia by hematopoietic genome editing

Blood (2021) 137 (12): 1628–1640.

https://doi.org/10.1182/blood.2020009103

Published: 2021

Includes: Supplemental data

Journal Articles

MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis

Xinfang Yu, Wei Li, Qipan Deng, Haidan Liu, Xu Wang, Hui Hu, Ya Cao, Zijun Y. Xu-Monette, Ling Li, Mingzhi Zhang, Zhongxin Lu, Ken H. Young, Yong Li

Blood (2021) 137 (12): 1615–1627.

https://doi.org/10.1182/blood.2020004918

Published: 2021

Includes: Supplemental data

Journal Articles

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

Lili Song, Bo Yu, Yi Yang, Jianwei Liang, Yingwen Zhang, Lixia Ding, Tianyi Wang, Xinyu Wan, Xiaomin Yang, Jingyan Tang, Shengyue Wang, Benshang Li, Yanxin Li, Haizhong Feng

Blood (2021) 137 (9): 1181–1191.

https://doi.org/10.1182/blood.2020005622

Published: 2021

Includes: Supplemental data

Journal Articles

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

Blood (2020) 136 (8): 957–973.

https://doi.org/10.1182/blood.2019002548

Published: 2020

Includes: Supplemental data

Journal Articles

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

Tatsuro Watanabe, Satoshi Yamashita, Hiroshi Ureshino, Kazuharu Kamachi, Yuki Kurahashi, Yuki Fukuda-Kurahashi, Nao Yoshida, Naoko Hattori, Hideaki Nakamura, Akemi Sato, Atsushi Kawaguchi, Naoko Sueoka-Aragane, Kensuke Kojima, Seiji Okada, Toshikazu Ushijima, Shinya Kimura, Eisaburo Sueoka

Blood (2020) 136 (7): 871–884.

https://doi.org/10.1182/blood.2019003084

Published: 2020

Includes: Supplemental data

Journal Articles

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

Tomoyasu Jo, Momoko Nishikori, Yasunori Kogure, Hiroshi Arima, Katsuhiro Sasaki, Yoshiteru Sasaki, Tomoko Nakagawa, Fumie Iwai, Shuji Momose, Aki Shiraishi, Hiroshi Kiyonari, Noritaka Kagaya, Tetsuo Onuki, Kazuo Shin-ya, Minoru Yoshida, Keisuke Kataoka, Seishi Ogawa, Kazuhiro Iwai, Akifumi Takaori-Kondo

Blood (2020) 136 (6): 684–697.

https://doi.org/10.1182/blood.2019002654

Published: 2020

Includes: Supplemental data

Journal Articles

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

Blood (2020) 136 (4): 387–400.

https://doi.org/10.1182/blood.2019003267

Published: 2020

Includes: Supplemental data

Journal Articles

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS

Blood (2020) 135 (25): 2271–2285.

https://doi.org/10.1182/blood.2019001963

Published: 2020

Includes: Supplemental data

Journal Articles

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation

Cornelius Pauli, Yi Liu, Christian Rohde, Chunhong Cui, Daria Fijalkowska, Dennis Gerloff, Carolin Walter, Jeroen Krijgsveld, Martin Dugas, Bayram Edemir, Caroline Pabst, Lutz P. Müller, Fengbiao Zhou, Carsten Müller-Tidow

Blood (2020) 135 (23): 2059–2070.

https://doi.org/10.1182/blood.2019004121

Published: 2020

Includes: Supplemental data

Journal Articles

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

Hai Vu Nguyen, Cassandra J. Vandenberg, Ashley P. Ng, Mikara R. Robati, Natasha S. Anstee, Joel Rimes, Edwin D. Hawkins, Suzanne Cory

Blood (2020) 135 (13): 1019–1031.

https://doi.org/10.1182/blood.2019003014

Published: 2020

Includes: Supplemental data

Journal Articles

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia

Yajian Jiang, Tianyuan Hu, Tao Wang, Xiangguo Shi, Ayumi Kitano, Kenneth Eagle, Kevin A. Hoegenauer, Marina Y. Konopleva, Charles Y. Lin, Nicolas L. Young, Daisuke Nakada

Blood (2019) 134 (24): 2183–2194.

https://doi.org/10.1182/blood.2019001076

Published: 2019

Includes: Supplemental data

Journal Articles

Non-Coding HOX Fusions in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia

Fabienne R.S. Adriaanse, MSc, Sadie M. Sakurada, B.A., Shondra M. Pruett-Miller, PhD, Ronald W. Stam, PhD, Michel C Zwaan, MD PhD, Tanja A. Gruber, MD PhD

Blood (2019) 134 (Supplement_1): 533.

https://doi.org/10.1182/blood-2019-127014

Published: 2019

Journal Articles

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Franck Morschhauser, MD PhD, Herve Tilly, MD PhD, Aristeidis Chaidos, Tycel J. Phillips, MD, Vincent Ribrag, MD, Philip Campbell, MBBS, FRACP, FRCPA, Damaj Gandhi Laurent, MD PhD, Wojciech Jurczak, MD PhD, Pamela McKay, MD, Stephen Opat, John Radford, Jennifer Whalen, Anand Rajarethinam, Susan Benedict Navia, Deyaa Adib, Gilles Salles, MD PhD

Blood (2019) 134 (Supplement_1): 123.

https://doi.org/10.1182/blood-2019-128096

Published: 2019

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

What’s new in the pathogenesis and treatment of therapy-related myeloid neoplasms

The bidirectional increased risk of B-cell lymphoma and T-cell lymphoma

Targeting the plasticity of mesenchymal stromal cells to reroute the course of acute myeloid leukemia

The essential reading list for AML: the m 6 A transcripts

Blocking RiBi to suppress MYC lymphomagenesis

A JAK/STAT-mediated inflammatory signaling cascade drives oncogenesis in AF10-rearranged AML

Emerging therapies for inv(16) AML

Modeling and targeting of erythroleukemia by hematopoietic genome editing

MYD88 L265P elicits mutation-specific ubiquitination to drive NF-κB activation and lymphomagenesis

Identification of functional cooperative mutations of GNAO1 in human acute lymphoblastic leukemia

The EMT modulator SNAI1 contributes to AML pathogenesis via its interaction with LSD1

Targeting aberrant DNA hypermethylation as a driver of ATL leukemogenesis by using the new oral demethylating agent OR-2100

LUBAC accelerates B-cell lymphomagenesis by conferring resistance to genotoxic stress on B cells

CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia

SETD2 deficiency accelerates MDS-associated leukemogenesis via S100a9 in NHD13 mice and predicts poor prognosis in MDS

Site-specific methylation of 18S ribosomal RNA by SNORD42A is required for acute myeloid leukemia cell proliferation

Development and survival of MYC-driven lymphomas require the MYC antagonist MNT to curb MYC-induced apoptosis

AMP-activated protein kinase links acetyl-CoA homeostasis to BRD4 recruitment in acute myeloid leukemia

Non-Coding HOX Fusions in Pediatric Non-Down Syndrome Acute Megakaryoblastic Leukemia

Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma

Email alerts

ASH Publications

American Society of Hematology